Company Announcement / Press release Archives - Page 7 of 17

Notice of annual general meeting of Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ), Reg. No. 556649-3671, are summoned to the annual general meeting on Thursday 19 May 2022. Pursuant to temporary legislation, Xspray Pharma’s annual general meeting will be carried out through advance voting (postal voting) only. No meeting with the possibility to attend in person or to be represented by […]

Xspray Pharma publishes its annual report for 2021

“In 2021, we once again confirmed that Xspray Pharma’s unique technology platform can produce amorphous versions of protein kinase inhibitors. Having our processes in place means that we can shorten the development time for new products. I look forward to an intensive and productive 2022, during which Xspray Pharma’s organization will develop and mature, and […]

Update on recent developments regarding Dasynoc

Xspray Pharma AB (publ), (Nasdaq Stockholm: XSPRAY) today announced an update on recent developments regarding Xspray Pharma’s first product, Dasynoc, currently under review by the United States Food & Drug Administration (“FDA”). Bristol Myers Squibb (“BMS”) has filed a lawsuit in the United States District Court for the District of New Jersey against Xspray Pharma […]

Xspray Pharma publishes Q4 Year-End report 2021

”When looking back at Xspray Pharma’s fourth quarter 2021, I see it marked by hope for the future. After the end of the quarter, we reached a significant milestone when the US Food and Drug Administration (FDA) announced that it had agreed to review Xspray Pharma’s first product candidate: Dasynoc, an improved version of dasatinib. […]

Xspray Pharma appoints Global Head of Marketing and Sales

Xspray Pharma AB (publ), (Nasdaq Stockholm: XSPRAY) announced today that the company has hired Anna-Karin Ekberg as Global Head of Marketing and Sales. She will take office in mid-March 2022. “At the beginning of the year, Xspray Pharma reached a substantial milestone when the FDA accepted to review our first product. This means that we are getting […]

FDA allows review of application for market approval for Xspray Pharma’s Dasynoc™

Xspray Pharma (publ) (Nasdaq Stockholm: XSPRAY) announced today that the US Food and Drug Administration (FDA) has agreed to review the company’s application for market approval for Xspray Pharma’s product candidate, Dasynoc™ (dasatinib) in the US under the 505(b)(2) process. In November 2021, Xspray Pharma submitted an application for market approval in the US of […]

Number of shares and votes in Xspray Pharma

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the number of shares and votes in Xspray Pharma AB has changed as a result of shares being registered due to the directed share issue which was carried out in November 2021. Through the direct share issue, carried out in November 2021, the number of outstanding […]

Xspray Pharma submits application for market approval to FDA for its product candidate Dasynoc

Xspray Pharma (publ) (Nasdaq Stockholm: XSPRAY) announces today that the application for US market approval of its first product candidate Dasynoc (dasatinib) has been submitted, in accordance with plans, to the Food and Drug Administration (FDA) under the 505(b)(2) NDA procedure, which is the registration path that applies to improved drugs. The application consists of […]

Xspray Pharma strengthens the organization with IR and Communications function

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) today announces that the company is strengthening its organization by creating an Investor Relations and Communications function. Christina Malmberg Hägerstrand has been appointed Vice President and Head of Investor Relations and Communications, she joins Xspray Pharma in January 2022. “With the development of Xspray Pharma and the initial […]

Xspray Pharma completes a directed new share issue to Flerie Invest, raising approximately SEK 100 million

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) today announces that the board of directors has resolved on a directed new share issue of 1,612,904 shares at a price of SEK 62 per share, corresponding to in total approximately SEK 100 million. The board of directors of Xspray Pharma has, based on the authorisation granted by […]